8-2-2008

Growth hormone therapy improves growth in children with cystic fibrosis related liver disease

Michael S. Stalvey
University of Massachusetts Medical School

Daniel M. Torrez
University of Florida

Jennifer Hillan
University of Florida

See next page for additional authors

Follow this and additional works at: http://escholarship.umassmed.edu/peds_endocrinology

Part of the Endocrinology, Diabetes, and Metabolism Commons, and the Pediatrics Commons

Repository Citation
http://escholarship.umassmed.edu/peds_endocrinology/16

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Endocrinology/Diabetes by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Growth hormone therapy improves growth in children with cystic fibrosis related liver disease

Authors
Michael S. Stalvey, Daniel M. Torrez, Jennifer Hillan, Regino P. Gonzalez-Perez, Allah Haafiz, and Arlan L. Rosenbloom

Rights and Permissions
Citation: J Pediatr Endocrinol Metab. 2008 Aug;21(8):793-7. Link to article on publisher's website

This article is available at eScholarship@UMMS: http://escholarship.umassmed.edu/peds_endocrinology/16
Growth Hormone Therapy Improves Growth in Children with Cystic Fibrosis Related Liver Disease

Michael S. Stalvey1,4, Daniel M. Torrez2, Jennifer Hillan2, Regino P. Gonzalez-Peralta3, Allah Haafiz3 and Arlan L. Rosenbloom1

University of Florida, Department of Pediatrics, 1Division of Pediatric Endocrinology, 2Division of Pediatric Pulmonology and 3Division of Pediatric Gastroenterology, Gainesville, FL and 4University of Massachusetts, Department of Pediatrics, Worcester, MA, USA

ABSTRACT

Growth impairment in cystic fibrosis (CF) is worsened by liver disease. Children with CF have serum levels of insulin-like growth factor-I (IGF-I) that are lower than expected for their normal growth hormone (GH) production. In children with CF-related liver disease (CFLD), response to endogenous GH is further reduced. We present our experience with two young children with CFLD given recombinant human GH (rhGH). The first patient was a 5 year-old female with CFLD and poor growth who responded well for ½ years to rhGH therapy during her initial course and without a significant increase in serum IGF-I, but with a substantial increase in IGF-I concentration when the GH dose was increased. The second patient was a 5 month-old male with advanced liver disease who had transient improved growth and liver function following rhGH. These patients suggest that rhGH is safe and may be effective in children with CFLD.

KEY WORDS
growth hormone, insulin like growth factor-I, cystic fibrosis, liver disease

INTRODUCTION

In 1938, the mean life expectancy for children with cystic fibrosis (CF) was less than one year, improving to 16 years by the mid-1970s and currently to 36.5 years1,2. Resulting from a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, CF has an incidence of one in 3,500 live births2. Some manifestations of this disease are due to defective CFTR chloride channel function and others are the result of cellular responses to mutant CFTR3-5. The interplay of these effects, with poor nutrient absorption and increased metabolic demand of illness, is thought to account for poor growth, although direct effects on growing bone and muscle cannot be discounted. Childhood height and weight for age are independent predictors of lung function and survival6,7.

Children with CF have normal growth hormone (GH) secretion, but low serum insulin-like growth factor-I (IGF-I) concentrations8. With CF-related liver disease (CFLD) IGF-I levels may be further reduced9. GH stimulation of hepatic production of IGF-I is the main source of circulating IGF-I. GH also stimulates hepatic production of the principal binding protein of circulating IGF-I, IGFBP-3 and the acid labile subunit (ALS). Some 90% of IGF-I circulates as a ternary complex with IGFBP-3 and ALS, the latter stabilizing the complex10. Administration of recombinant human GH (rhGH) may improve growth by stimulating IGF-I synthesis in the liver (endocrine) and bone (paracrine), as well as directly stimulating pre-chondrocyte differentiation. Studies suggest that rhGH treatment improves the growth and clinical course in patients with CF11,12. More specifically, rhGH administration has been associated with increased lean body mass, improved lung
function, and decreased hospitalizations.

We have treated two children with low IGF-I production and impaired growth, despite substantial caloric intake. Adequacy of endogenous GH production was determined in both children. We hypothesized that the addition of exogenous rhGH would stimulate target tissues to improve IGF-I production.

PATIENT REPORTS

Patient 1

This child had mild lung disease with infrequent respiratory symptoms, despite being homozygous for the ΔF508 mutation. She was too young for reliable pulmonary function testing. She had hepatomegaly and markedly elevated serum transaminase levels at 4 months of age. Diagnosed with chronic liver disease, she had been stable on medical therapy for >2 years.

At 5 years of age, standard deviation score (SDS) for height was -4 and for weight -3.9, with poor growth velocity (GV), of 3.5 cm/yr (-4 SDS). Her pre-albumin level was low (12 mg/dl [normal {nl}: 20-40]) despite gastrostomy tube and oral intake, which was greater than calculated energy needs of 135 kcal/kg/day. Thyroid, adrenal function and blood glucose levels were normal. After a GH stimulation test using glucagon and clonidine resulted in a peak response of 9.9 ng/ml, we initiated treatment with rhGH (0.3 mg/kg/wk). Her intake improved slightly, from 171 to 194 kcal/kg/day. She had suboptimal weight gain in the 12 months before (2.8 g/d) and after (3.1 g/d, nl for age 5-8 g/d) starting rhGH. Nonetheless, GV increased to 8.4 cm/yr over the first 6 months of rhGH treatment, but serum IGF-I and IGFBP-3 concentrations were unaffected (from 54 to 66 ng/ml for IGF-I [nl for age 57-260] and from 1.4 to 2.1 mg/l for IGFBP-3 [nl for age 1.1 to 5.2]). At 9 months into her therapy, her GV continued at 7.5 cm/yr, but by 12 months her growth slowed to 4 cm/year. We increased her rhGH dose to 0.35 mg/kg/wk. Her IGF-I level was obtained one month later and had increased to 183 ng/ml, and her AST and ALT normalized (from pretreatment 49 and 45 U/l to 35 and 39 U/l). In addition, her growth rate improved over the next 7 months to 6.4 cm/yr.

Patient 2

This 5 month-old male infant with CFLD and poor growth was born full term with a meconium cyst that was removed along with 15 cm of bowel in the neonatal period. CFTR genotyping revealed combined heterozygosity for the ΔF508 mutation and a nonsense allele (Q493X).

Total parenteral nutrition (TPN) was provided because of prolonged feeding difficulties, with inability to tolerate more than 200 ml/day through the gastrostomy tube without profuse diarrhea. He subsequently developed severe liver dysfunction, attributed to TPN and CF. Other complications included coagulopathy, ascites, esophageal varices, and gastric erosions. He was listed for liver transplantation; however, weight gain and linear growth were desired to improve outcome with transplantation.

Growth and weight gain were inadequate; length was 62.5 cm and weight was 6.04 kg, -1.3 SDS for length and -1.8 SDS for weight. His birth length was 48.3 cm (-0.65 SDS) and weight 2.75 kg (-1.3 SDS). At 5 months of age, his weight for height was calculated at the 10th percentile. He had jaundice and hepatomegaly. Laboratory studies were remarkable for a total bilirubin of 24.3 mg/dl, with a conjugated fraction of 22.1. His serum AST and ALT concentrations were 508 and 341 U/l, respectively. PT and PTT were mildly elevated and the pre-albumin level in serum was low. Endocrine evaluation revealed normal thyroid function and GH production; peak random GH level was 18.4 ng/ml: Although serum IGF-I was undetectable, IGFBP-3 and ALS levels were normal (0.7 mg/l [nl for age 0.7-3.6] and 1.5 mg/l [nl for age 0.7-5.6], respectively), indicating some hepatic response to endogenous GH.

Treatment with rhGH was begun in an effort to improve growth and weight, and accelerate the transition to enteral feeds. His growth immediately improved. Within one month, his length was -0.6 SDS and his weight was -1.3 SDS. There was an improvement in muscle mass and tone and in overall physical activity. In addition, he was transitioned to full enteral feeds within six weeks. No other changes to his care were introduced. His serum transaminase concentrations improved, and
total and conjugated bilirubin levels decreased to 12.8 and 11.2, respectively. Coagulation studies and pre-albumin concentrations normalized. IGF-I reached detectable levels. Plans for liver transplantation were postponed.

Improvement did not persist, however. Approximately two months into therapy, weight gain and linear growth rates declined, liver function deteriorated, and he developed persistent coagulopathy. His weight dropped to that before treatment and growth rate decreased below normal for his age. Serum IGF-I concentration also fell below the normal range. Successful transition to enteral feeds was one of the decisive factors to pursue liver transplantation. At 10 months of age, he received his liver transplant and is doing well.

**DISCUSSION**

The use of rhGH for growth promotion in individuals with CF is increasing. There is, however, no safety and efficacy experience with rhGH treatment in patients with CFLD. Impaired liver function could result in impaired IGF-I production despite normal GH secretion. GH has both direct effects on growing bone differentiation and indirect growth effects through IGF-I produced by the liver or other tissues. One mechanism for the positive responses to GH seen in children with CF may be increased direct effects of GH and increased local production of IGF-I in growing tissues.

Our first patient had an initial dramatic improvement in GV without an increase in circulating IGF-I concentrations, implying a local effect of pharmacological levels of GH in growing bone. Local GH effects are differentiation and proliferation of chondrocytes with stimulation of paracrine IGF-I synthesis. CFTR expression in osteoblasts indicates a possible mechanism for CF-related growth failure. Extremely low serum IGF-I concentration is seen with normal or near-normal growth in hepatic IGF-I or ALS knockout mice and ALS gene mutation in humans, indicating that the direct effects of GH in growing tissues and local (paracrine) production of IGF-I may be sufficient for normal growth.

We concluded that the low serum IGF-I concentration in patient 1 was the result of CFLD and not directly related to the growth problem. Therefore, IGF-I may not be a good marker for determining candidates for rhGH therapy or for the efficacy of rhGH therapy in CFLD. Subsequently, the increase in circulating IGF-I concentration following the increased dosage also coincided with normalization of the liver transaminase level in serum. It is not possible to distinguish whether this improvement was secondary to the increased dose or improved liver function. In either case, the improved liver function and IGF-I production were, paradoxically, associated with a decline in GV.

Effects of GH on the liver are unclear. Neonatal hepatitis secondary to cholestasis occurs with congenital GH deficiency. Animal models suggest an integral role for GH in liver regeneration. Pennisi et al. performed partial (70%) hepatectomies in three groups of mice: a) GH antagonist transgenic mice, in which the action of GH is blocked, b) liver IGF-I deficient mice that also lacked ALS, and c) control animals with normal GH and IGF-I levels. GH antagonist mice demonstrated the worst survival rate immediately following surgery (57%) compared to the IGF-I and ALS deficient mice (88%) and controls (100%). Following partial hepatectomy, control mice were able to fully regenerate their liver mass by four days. IGF-I and ALS deficient mice were able to fully regenerate their liver to the original mass by seven days. The GH antagonist mice that survived were only able to regenerate to 70% of their original liver mass by four days, and did not regenerate further before sacrifice at seven days. Desbois-Mouthon et al. further describe the complex paracrine interaction of IGF-I at the rodent liver. Their group utilized a liver IGF-I receptor inactivation mouse to demonstrate a need for upregulation (from the minimal baseline state) of the IGF-I receptor during liver regeneration.

The second patient had a relatively uncommon indication for rhGH treatment in children. GH is indicated for treatment of short gut syndrome in adults, although the data on effectiveness are conflicting. Shulman et al. reported an increase in the mucosal height following GH therapy in rats that had previously...
undergone 75% resection of the ileum\textsuperscript{26}. Regeneration of rat gut mucosa has been improved with the addition of glutamine to GH therapy\textsuperscript{27}. Although the short gut syndrome indication for rhGH is not exclusive to adults, experience in children is limited\textsuperscript{28,29}.

The infant patient suffered from the various effects of CF with end-stage liver disease, short gut syndrome, and severe growth failure. He had an initial therapeutic response to rhGH, including an increase in weight gain and linear growth, with a successful transition to enteral feedings, and an increase in circulating IGF-I concentration. These findings suggest that early in the course of CFLD, rhGH may be useful. As liver disease progresses and chronic catabolism ensues, however, the ability of the liver and other target tissues to mount an IGF-I response to GH may be lost.

Researchers have examined GH therapy for other catabolic states, primarily in the adult population. The most extensively studied indication for rhGH in adult catabolism is for HIV-associated wasting. In 2004, Moyle \textit{et al.} reported improvements in lean body mass, physical performance and quality of life in a large (757 patients) randomized, double-blind, placebo-controlled trial of rhGH in HIV\textsuperscript{30}. Other studies have tried to reverse the catabolic state and overcome resistance to GH. Wallace \textit{et al.} observed improvements in serum levels of IGF-I, IGFBP-3 and ALS in a randomized, double-blind, placebo-controlled, cross-over study of GH therapy in nine adults with chronic liver disease\textsuperscript{31}. In addition, there was an improvement in lean tissue mass of approximately 10% (measured by total body potassium and bioelectrical impedance). Worsening ascites and edema were noted, however, in four of the individuals. Neither of our patients demonstrated worsening of ascites or edema during rhGH therapy. Nonetheless, this complication should be considered when treating children with hypoproteinemia or ascites.

Both patients illustrate that rhGH therapy may be used in children with CFLD. No adverse events were associated with rhGH therapy. Both children demonstrated a noticeable increase in growth despite their liver disease. Variable biochemical responses were noted following GH augmentation, suggesting more important direct GH effects on growing tissue and in stimulating paracrine IGF-I production. These findings suggest the need for additional studies into the biochemical effects of GH treatment on individuals with CF, as well as in individuals with liver disease.

\section*{References}


